A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Clinical trial NCT02076412 · COMPLETED

Trial details

NCT number: NCT02076412
Sponsor: Rigel Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Immune Thrombocytopenic Purpura

Start date: 2015-01-01
Primary completion: 2016-08-01
Enrollment: 74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.